Even if it's not a huge purchase, we think it was good to see that Daniel Junius, the Independent Director of GlycoMimetics, Inc. (NASDAQ:GLYC) recently shelled out US$68k to buy stock, at US$3.40 per ...

Daniel M. Junius We’ll disclose the information that we have about the two doses when we present data, which as we said early we’re hoping to submit to ASCO. So that level of information has not been ...

IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today ...

Having worked in the insurance claims industry for more than five decades, Daniel M. Junius had seen it all. Family members recalled how the father of six loved sharing stories around the dinner table ...